Anaphylactoid reaction to cyclophosphamide in a patient with T cell lymphoma and hemophagocytic syndrome.
Minami
R
R
Hirase
N
N
Motomura
S
S
Muta
K
K
Nawata
H
H
Nishimura
J
J
D000707:Anaphylaxis / Q000139:chemically induced*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects*; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D015616:Histiocytosis, Non-Langerhans-Cell / Q000209:etiology*; D006801:Humans; D016399:Lymphoma, T-Cell / Q000150:complications* / Q000188:drug therapy; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D018906:Antineoplastic Agents, Alkylating; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone